GSA Capital Partners LLP Lowers Stock Holdings in Cerus Co. (NASDAQ:CERS)

GSA Capital Partners LLP decreased its position in Cerus Co. (NASDAQ:CERS - Free Report) by 34.5% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 959,978 shares of the biotechnology company's stock after selling 505,044 shares during the period. GSA Capital Partners LLP owned approximately 0.52% of Cerus worth $1,670,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Hood River Capital Management LLC acquired a new stake in Cerus during the first quarter valued at approximately $566,000. The Manufacturers Life Insurance Company lifted its stake in Cerus by 10.9% during the second quarter. The Manufacturers Life Insurance Company now owns 73,372 shares of the biotechnology company's stock valued at $129,000 after purchasing an additional 7,209 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Cerus by 4.9% during the first quarter. Price T Rowe Associates Inc. MD now owns 192,873 shares of the biotechnology company's stock valued at $365,000 after purchasing an additional 8,982 shares during the last quarter. Russell Investments Group Ltd. lifted its stake in Cerus by 451.1% during the first quarter. Russell Investments Group Ltd. now owns 14,879 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 12,179 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in shares of Cerus by 7.1% during the second quarter. Assenagon Asset Management S.A. now owns 1,186,564 shares of the biotechnology company's stock valued at $2,088,000 after acquiring an additional 78,824 shares during the period. Institutional investors own 78.37% of the company's stock.

Cerus Stock Performance

Shares of CERS stock traded down $0.03 on Wednesday, reaching $1.86. 920,775 shares of the company were exchanged, compared to its average volume of 1,299,177. The company has a 50-day moving average of $1.80 and a 200-day moving average of $1.92. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. Cerus Co. has a one year low of $1.38 and a one year high of $2.59.

Insider Activity at Cerus

In other Cerus news, CFO Kevin Dennis Green sold 28,385 shares of the company's stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $2.18, for a total value of $61,879.30. Following the completion of the transaction, the chief financial officer now owns 590,365 shares in the company, valued at $1,286,995.70. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 3.40% of the stock is owned by insiders.

Analyst Ratings Changes

Separately, Stifel Nicolaus dropped their price objective on shares of Cerus from $6.00 to $3.00 and set a "buy" rating on the stock in a research note on Thursday, October 17th.

Cerus Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.